A fully-loaded product pipeline in various stages of clinical development, Nobel Prize-winning advisors, partnerships with the University of Oxford and Yale University — and much more. At the heart of each one of our initiatives is a commitment to rigorous scientific research.

Product Pipeline

Our current pipeline includes preclinical and clinical trials for skin, microbiome, muscle, cognition, UV damage, menopausal syndromes, and circadian rhythm. Beyond Basis, Matter, Format, Signal, Mosaic, and Index, we are working with our scientific advisors and university partners to identify promising new research and innovative compounds.

These compounds are all tested for safety and efficacy in placebo-controlled human trials before coming to market.

As you can see from our preclinical studies and clinical trials outlined below, there’s a lot happening behind the scenes at Elysium — and a lot to look forward to.

Clinical Trials

Clinical research is incredibly important to us. We study our products in humans so you can be confident that your decisions are based on scientific evidence.

Osteoporosis

Initiated at Odense University Hospital, this human clinical trial is evaluating the effect of NR-E or senolytics on bone resorption and formation markers in osteoporosis. The estimated study completion date is December 2025. ClinicalTrials.gov Identifier: NCT06018467

Age-Related Frailty

Initiated at Mayo Clinic, the human clinical trial will evaluate whether Elysium’s proprietary nicotinamide riboside (NR-E) can augment bone, skeletal muscle, and metabolic functions and structure in aging. The estimated primary study completion date is March 2024. ClinicalTrials.gov Identifier: NCT03818802

TIME-A

The Translational Initiative to Map Epigenetics in Aging (TIME-A) is a longitudinal, prospective research study that aims to advance our understanding of the connections between epigenetics, lifestyle, demographics, and health and aging. All Index users are eligible to enrollThe study can be found on www.clinicaltrials.gov under the identifier NCT05760547.

Slow Age

Initiated at the University of Copenhagen in Denmark, this human clinical trial evaluated the effects of nicotinamide riboside (NR-E), aerobic exercise, or time-restricted feeding on markers of aging. The study is complete and pending publication. ClinicalTrials.gov Identifier: NCT05593939

Brain Vascular Health

Initiated at the University of Oklahoma, this human clinical trial is evaluating the efficacy of NR-E on supporting brain vascular health and memory in aging. The estimated primary study completion date is June 2027. ClinicalTrials.gov Identifier: NCT05483465

Non-Alcoholic Fatty Liver (NAFL)

This six-month human clinical trial showed that Basis, at the recommended dose, reduced several markers of liver inflammation in healthy adults with fatty liver. The results, published in Hepatology, also further confirmed that Basis is safe and well tolerated and supports liver function in healthy individuals. Publication here. ClinicalTrials.gov Identifier: NCT03513523

Muscle Injury and Repair

Initiated in partnership with researchers at Aarhus University in Denmark, this study demonstrated that a combination of nicotinamide riboside and pterostilbene (NRPT) was well tolerated but did not improve recruitment of muscle stem cells after muscle injury in older adults. Muscle soreness, however, tended to be lower in the treatment group. Publication here. ClinicalTrials.gov Identifier: NCT03754842

Acute Kidney Injury (AKI) Phase I

Completed and published in BMC Nephrology, the Phase I human clinical trial, conducted in partnership with Massachusetts General Hospital, enabled the FDA approval of an Investigational New Drug application for Basis and the AKI Phase II trial.  Publication hereClinicalTrials.gov Identifier: NCT03176628

Acute Kidney Injury (AKI) Phase II

Initiated at Mayo Clinic, this human clinical trial is evaluating the efficacy of Basis for the prevention of AKI in surgical cardiac patients. This study is estimated to complete in December 2023. ClinicalTrials.gov Identifier: NCT04342975

Repeat Dose Basis

Elysium’s first human clinical trial showed that a daily dose of Basis safely and sustainably increases NAD+ levels by an average of 40% from baseline–by middle age, our NAD+ levels decline by approximately 50%. The study was published in Nature Partner Journals: Aging and Mechanisms of Disease. Publication here. ClinicalTrials.gov Identifier: NCT02678611

Menopausal Syndromes

Working in partnership with the University of South Alabama, this pilot study evaluated the effects of Basis supplementation on menopausal syndromes. The study is complete and expected to publish in 2024. ClinicalTrials.gov Identifier: NCT04841499

EH301 for ALS

Working in collaboration with the Spanish Foundation for ALS Research (FUNDELA), the results of this pilot study showed evidence the experimental therapeutic EH301 can be used in treatment of amyotrophic lateral sclerosis (ALS). Publication here. ClinicalTrials.gov Identifier: NCT03489200

NO-ALS (EH301)

Initiated with partners at Haukeland University Hospital and funded by a grant from the Norwegian government, this human clinical trial is evaluating the efficacy of the experimental therapeutic EH301 for the potential treatment of ALS. We expect the study to be completed by the end of 2024. ClinicalTrials.gov Identifier: NCT04562831

COPD (NR-E)

Initiated at the University of Copenhagen and funded by a grant from the Danish government, this clinical trial evaluated the effect of Elysium’s proprietary nicotinamide riboside (NR-E) on clinical outcomes in elderly patients with COPD. The study results, which are in pre-print, showed that NR-E supplementation supported a healthy inflammation response in the lungs. ClinicalTrials.gov Identifier: NCT04990869

Academic Partnerships

We’ve established multi-year research partnerships with leading institutions to break new ground in aging research.
Oxford University - Elysium Health

Partnership with the University of Oxford

Matter, our breakthrough product clinically proven to slow age-related brain atrophy, was developed in partnership with the University of Oxford and world-renowned scientist A. David Smith, Ph.D., Professor Emeritus of Pharmacology at the University of Oxford, Founding Director of OPTIMA, and Elysium Scientific Advisory Board member.

The Oxford-Elysium Fellowship Program - Elysium Health

The Oxford-Elysium Fellowship Program

Elysium has established the Oxford-Elysium Fellowship program at the University of Oxford, which recruits the best researchers to work in cutting-edge laboratories. 

The first fellow, Hanlin Zhang, discovered a new pathway for autophagy induction. Zhang works in the lab of Katja Simon, Professor of Immunology in the Kennedy Institute of Rheumatology in the Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences. Elysium owns first rights to all intellectual property developed by the fellow.

The second fellow, Adam Rolt, works in the lab of Lynne Cox at the University of Oxford’s Cox Lab of Ageing and Cell Senescence. Cox’s lab focuses on the genes and biochemical pathways that influence health outcomes in aging and promote healthy aging by treating age-related diseases at the cause.

Lewis Taylor is the third fellow in the Oxford-Elysium program, and works in Aarti Jagannath’s lab at the Nuffield Department of Clinical Neuroscience. Taylor’s focus is on researching the relationship between circadian rhythms, chronic disease, and biological age.

For further details on the Oxford-Elysium program and how to apply for fellowship, read more.

Partnership With Yale University - Elysium Health

Partnership With Yale University

Elysium partnered with Morgan Levine, Ph.D., of Yale University and a leading researcher in the field of epigenetic predictors of age to develop Index, our revolutionary at-home epigenetic test.

Elysium Scholars: Helping Students Study Science - Elysium Health

Elysium Scholars: Helping Students Study Science

Elysium’s scholarship program is designed to encourage and assist students pursuing an education in science-related fields. There are currently six students enrolled in an undergraduate degree in a scientific field benefiting from the scholarship.

“Through Elysium Health's products and research focus on human health, the Elysium Scholars program takes an expansive approach to science. We believe that encouraging young people to pursue a career in any scientific field is a critical step toward future breakthroughs and innovations that may have a meaningful impact on the overall health of our society." - Elysium co-founder and chief scientist Leonard Guarente, Ph.D.

Elysium Scholars is not currently accepting new applicants.